Yohimbine Hydrochloride

Phase 3Small molecule

UUnknown Sponsor

Yohimbine Hydrochloride is one of 25 small molecule programs targeting Anxiety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

AnxietyPhase 3

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Anxiety

#DrugCompanyPhaseTrials

Valium

Akero Therapeutics

Phase 3

2 2

Chamomile

HHams Hamed Abdelrahman

Phase 3

1 3

Yohimbine Hydrochloride

UUnknown Sponsor

Phase 3

1 4

Celexa

AbbVie

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

4 6

Luvox

SSolvay Pharmaceuticals

Preclinical

2 7

Anerem

AAcacia Pharma Ltd

Preclinical

2 8

Campral

FForest Laboratories

Preclinical

2 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Andriol

AAuxilium

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Stress

NCT06430580

Clinical

Trials by Indication[1]

ART1 trial

The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery

Completed·MMedical University of Vienna·Phase 4·NCT00814047·18 enrolled

Stress1 trial

Cannabinoids and Biological Reactivity to Stress

Recruiting·FFlorida State University·Phase 1·NCT06430580·36 enrolled

Anxiety1 trial

Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety

Completed·UUnknown Sponsor·Phase 3·NCT00958880·40 enrolled

Current Smoker1 trial

Investigation of Nicotine Seeking Behavior in Current Smokers

Completed·WWayne State University·Phase 1·NCT03670212·21 enrolled

Major Depression1 trial

Rapid Antidepressant Effects of Yohimbine in Major Depression

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00078715·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Yohimbine Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yohimbine Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yohimbine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUnknown Sponsor

Yohimbine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

ART1 trial

Stress1 trial

Anxiety1 trial

Current Smoker1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News